Priority topics

Areas covered will include:

• Breathlessness (diagnosis and management).
• Precision rehabilitation: personalised indications, programmes, outcomes.
• Asthma diagnosis (adults and children).
• An aging lung: respiratory disease in elderly.
• Digital solutions: a new way of working.

Areas covered will include:

• Weaning from mechanical ventilation: lessons from WEAN-SAFE.
• Lung ultrasound in acute respiratory care.
• Advanced care planning in long-term mechanical ventilation.
• Setting up chronic ventilation: what are the needs for different diseases?

Areas covered will include:

• Mechanisms responsible for progression of pulmonary diseases.
• Cross-talk: inter-organ and cell-to-cell communication strategies in lung health and disease.
• Innovative strategies for lung repair including cell and extracellular-vesicle based therapy in lung disease.
• Exacerbations, imbalanced immunity and cellular plasticity in lung disease.
• Disrupted lung homeostasis, from fibrosis to cancer.

Areas covered will include:

• New diagnostic tools for sleep disordered breathing.
• Sleep apnea and comorbit sleep disorders.
• Obesity and the lung: from wakefulness to sleep.
• Where we stand with non-CPAP therapies: from bench to bedside.
• Sleep disorders to obstructive and restrictive respiratory diseases.

Areas covered will include:

• Inflammation in airways diseases: which compartment matters; nasal, large, small airways or blood?
• New drugs in asthma, COPD and chronic cough.
• New insights into small airways disease: pathology, physiology, pharmaceutics and patient outcomes.
• Techniques to detect airway inflammation: time for an update.
• Treatable traits in COPD.

Areas covered will include:

• Determinants (including airborne pollutants) of lung health in non-smoking adults.
• Air pollution, emission sources, desert dust storms and climate change: impact on lung health.
• Towards chronic respiratory disease prevention through occupational and environmental exposure management.
• What have we learned from the longitudinal general population surveys in respiratory epidemiology over the last fifty years?
• What pandemics should have taught us: preventing disease and disability from occupational respiratory infections?

Areas covered will include:

• Childhood onset lung disease into adulthood.
• Determinants of lung function trajectories from infancy to adulthood.
• Diagnostic tools for PCD disease: where are we at?
• Severe asthma: what is a good response to biologics?
• Genetic testing in paediatric respiratory diseases.

Areas covered will include:

• Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: the key role of the multidisciplinary team in the decision-making process.
• Feasibility and surgical outcomes of video-assisted thoracoscopic pulmonary resection in patients with advanced-stage lung cancer after neoadjuvant chemoradiotherapy.
• Lung fungal infection and co-infection in immunocompetent and immunosuppressed patients (from COVID 19 to bone marrow or lung transplant recipients).
• Thoracoscopic versus open lobectomy after induction therapy for non-small cell lung cancer: surgical outcomes.
• Electromagnetic navigation transthoracic nodule localization for minimally invasive thoracic surgery.

Areas covered will include:

• Emerging technologies and AI in physiological assessment.
• Short functional testing in chronic lung disease.
• Long-term complications of COVID-19: assessment and pulmonary rehabilitation.
• Patient assessment and implementation of homebased pulmonary rehabilitation.
• Empowering health care workers to use digital technology.

Areas covered will include:

• Emerging infectious diseases.
• Future of tuberculosis drugs and regimens.
• Future of tuberculosis drugs and regimens
• How to manage chronic nontuberculous mycobacteria
• Biomarkers in respiratory infection. What is the present and what can we aim in the future?
• How to deal with the adverse events of anti-tuberculosis drugs?

Areas covered will include:

• Optimal lung cancer management of early stage/locally advanced NSCLC (incl. diagnostic algorithms to optimise lung cancer resection / radiotherapy and cure).
• CT screening and lung nodules.
• Stratification of malignant pleural effusion pathway: diagnostic and straight to biopsy (biomarkers, imaging).
• Early stage mesothelioma: Mars2 and some other data? Late-stage treatments for early stage.
• Endoscopy, including NMR, robotic and navigation bronchoscopy.

Areas covered will include:

• The future of ILD.
• Management of fibrosing non-IPF ILDs.
• Combining immunosuppressive drugs and antifibrotics in CTD-ILD: practical aspects.
• CTD-ILD: from screening to disease monitoring and treatment.
• Diagnosing and treating rare lung diseases.

Areas covered will include:

• Difficult treatment decisions in (intermediate) high risk and in critical situations.
• Pulmonary hypertension in lung and heart disease.
• Optimal follow-up of patients with pulmonary embolism.
• The origin of pulmonary hypertension (different concepts of disease).
• Radiology of pulmonary vascular diseases.

Areas covered will include:

• Pheripheral lung nodule; bronchoscopic (navigational) techniques, radiology and surgical techniques.
• Endoscopy, including NMR, robotic and navigation bronchoscopy.
• Interventional pulmonology course/skills workshop.
• CT screening and lung nodules.
• Mediastinal staging: the what and the how (incl. imaging techniques, novel sampling techniques).